Market research
ONXEO.PA Onxeo SA
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 1.7
- Dividend yield
- 0.0%
- Beta
- 1.69
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0010095596
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 1.7
- Dividend yield
- 0.0%
- Beta
- 1.69
About
About Onxeo SA
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ONXEO.PA discussion.
5 years, 5 months ago
Onxeo SA is currently in a long term uptrend where the price is trading 3.7% above its 200 day moving average.
From a valuation standpoint, the stock is 95.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.4.
Based on the above factors, Onxeo SA gets an overall score of 2/5.